[144] ANI Pharmaceuticals, Inc. SEC Filing
ANI Pharmaceuticals (ANIP) Form 144 notice shows a proposed sale of 2,528 restricted common shares by or for an identified person through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $229,075.98 and an approximate sale date of 08/25/2025. The filing states those shares were acquired as restricted stock from the issuer on 08/21/2025 and paid for on that date. The form also discloses a separate sale by Matthew Leonard of 6,937 common shares on 08/18/2025 with gross proceeds of $611,644.31. The filer certifies they have no undisclosed material adverse information.
ANI Pharmaceuticals (ANIP) avviso Form 144 segnala la proposta di vendita di 2.528 azioni ordinarie soggette a restrizioni, da parte o per conto di un soggetto identificato, tramite Morgan Stanley Smith Barney su NASDAQ, per un valore di mercato complessivo di $229.075,98 e con data di vendita approssimativa 25/08/2025. La denuncia indica che quelle azioni sono state acquisite come azioni ristrette dall鈥檈mittente il 21/08/2025 e pagate in quella data. Il modulo riepiloga inoltre una vendita separata di Matthew Leonard di 6.937 azioni ordinarie il 18/08/2025, con proventi lordi di $611.644,31. Il dichiarante certifica di non avere informazioni materiali avverse non divulgate.
ANI Pharmaceuticals (ANIP) aviso Form 144 muestra una propuesta de venta de 2.528 acciones ordinarias restringidas por o en nombre de una persona identificada a trav茅s de Morgan Stanley Smith Barney en NASDAQ, con un valor de mercado agregado de $229.075,98 y una fecha aproximada de venta el 25/08/2025. El expediente indica que esas acciones fueron adquiridas como acciones restringidas del emisor el 21/08/2025 y abonadas en esa fecha. El formulario tambi茅n revela una venta separada por Matthew Leonard de 6.937 acciones ordinarias el 18/08/2025, con ingresos brutos de $611.644,31. El declarante certifica que no posee informaci贸n adversa material no divulgada.
ANI Pharmaceuticals (ANIP) Form 144 瓿奠嫓電� NASDAQ鞐愳劀 Morgan Stanley Smith Barney毳� 韱淀暣 頇曥澑霅� 臧滌澑鞚� 鞙勴暣 霕愲姅 頃措嫻 臧滌澑鞐� 鞚橅暣 2,528欤检潣 鞝滍暅 氤错喌欤� 毵る弰臧� 鞝滌晥霅橃棃鞚岇潉 氤挫棳欤茧┌, 齑� 鞁滌灔 臧�旃橂姅 $229,075.98鞚搓碃 鞓堨儊 毵り皝鞚检潃 2025雲� 8鞗� 25鞚检瀰雼堧嫟. 鞝滌稖靹滊鞐愲姅 頃措嫻 欤检嫕鞚� 2025雲� 8鞗� 21鞚� 氚滍枆鞚胳溂搿滊秬韯� 鞝滍暅欤茧 旆摑霅橃柎 攴鸽偁 雽�旮堨澊 歆�旮夒悩鞐堧嫟瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 靹滊電� 霕愴暅 Matthew Leonard鞚� 2025雲� 8鞗� 18鞚检棎 6,937欤茧ゼ 毵る弰頃橃棳 齑濎垬鞚� $611,644.31鞚� 鞏混棃雼る姅 氤勲弰鞚� 毵り皝霃� 瓿奠嫓頃╇媹雼�. 鞝滌稖鞛愲姅 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 鞚胳頃╇媹雼�.
ANI Pharmaceuticals (ANIP) avis Form 144 indique une proposition de vente de 2 528 actions ordinaires restreintes par ou pour une personne identifi茅e via Morgan Stanley Smith Barney sur le NASDAQ, pour une valeur de march茅 totale de 229 075,98 $ et une date approximative de vente au 25/08/2025. Le d茅p么t pr茅cise que ces actions ont 茅t茅 acquises en tant qu'actions restreintes aupr猫s de l'茅metteur le 21/08/2025 et pay茅es 脿 cette date. Le formulaire divulgue 茅galement une vente distincte par Matthew Leonard de 6 937 actions ordinaires le 18/08/2025, pour des produits bruts de 611 644,31 $. Le d茅clarant certifie qu'il n'existe aucune information d茅favorable mat茅rielle non divulgu茅e.
ANI Pharmaceuticals (ANIP) Form 144-Mitteilung weist auf einen geplanten Verkauf von 2.528 eingeschr盲nkten Stammaktien durch oder f眉r eine identifizierte Person 眉ber Morgan Stanley Smith Barney an der NASDAQ hin, mit einem Gesamtmarktwert von $229.075,98 und einem ungef盲hren Verkaufstermin am 25.08.2025. Die Einreichung gibt an, dass diese Aktien am 21.08.2025 als eingeschr盲nkte Aktien vom Emittenten erworben und an diesem Datum bezahlt wurden. Das Formular offenbart au脽erdem einen separaten Verkauf von 6.937 Stammaktien durch Matthew Leonard am 18.08.2025 mit Bruttoerl枚sen von $611.644,31. Der Einreicher best盲tigt, keine nicht offengelegten, wesentlichen nachteiligen Informationen zu haben.
- None.
- None.
Insights
TL;DR: Routine Rule 144 sale notice disclosing a small restricted-stock sale and a recent larger sale by Matthew Leonard.
The filing records a proposed sale of 2,528 restricted shares valued at $229,075.98 and a prior sale of 6,937 shares generating $611,644.31. For investors, this is a transfer disclosure rather than an operational update; it provides transparency about insider liquidity but contains no financial results or forecasts. No new material company information is presented beyond the transactions and timing.
TL;DR: Form 144 appears properly completed and includes required acquisition, sale and broker details.
The form specifies acquisition dates, nature of acquisition (restricted stock), broker identity, sale amounts, aggregate market value, and the seller's representation about material information. These elements align with Rule 144 disclosure requirements. The filing does not include any statements suggesting noncompliance or undisclosed material events; it is a routine compliance disclosure.
ANI Pharmaceuticals (ANIP) avviso Form 144 segnala la proposta di vendita di 2.528 azioni ordinarie soggette a restrizioni, da parte o per conto di un soggetto identificato, tramite Morgan Stanley Smith Barney su NASDAQ, per un valore di mercato complessivo di $229.075,98 e con data di vendita approssimativa 25/08/2025. La denuncia indica che quelle azioni sono state acquisite come azioni ristrette dall鈥檈mittente il 21/08/2025 e pagate in quella data. Il modulo riepiloga inoltre una vendita separata di Matthew Leonard di 6.937 azioni ordinarie il 18/08/2025, con proventi lordi di $611.644,31. Il dichiarante certifica di non avere informazioni materiali avverse non divulgate.
ANI Pharmaceuticals (ANIP) aviso Form 144 muestra una propuesta de venta de 2.528 acciones ordinarias restringidas por o en nombre de una persona identificada a trav茅s de Morgan Stanley Smith Barney en NASDAQ, con un valor de mercado agregado de $229.075,98 y una fecha aproximada de venta el 25/08/2025. El expediente indica que esas acciones fueron adquiridas como acciones restringidas del emisor el 21/08/2025 y abonadas en esa fecha. El formulario tambi茅n revela una venta separada por Matthew Leonard de 6.937 acciones ordinarias el 18/08/2025, con ingresos brutos de $611.644,31. El declarante certifica que no posee informaci贸n adversa material no divulgada.
ANI Pharmaceuticals (ANIP) Form 144 瓿奠嫓電� NASDAQ鞐愳劀 Morgan Stanley Smith Barney毳� 韱淀暣 頇曥澑霅� 臧滌澑鞚� 鞙勴暣 霕愲姅 頃措嫻 臧滌澑鞐� 鞚橅暣 2,528欤检潣 鞝滍暅 氤错喌欤� 毵る弰臧� 鞝滌晥霅橃棃鞚岇潉 氤挫棳欤茧┌, 齑� 鞁滌灔 臧�旃橂姅 $229,075.98鞚搓碃 鞓堨儊 毵り皝鞚检潃 2025雲� 8鞗� 25鞚检瀰雼堧嫟. 鞝滌稖靹滊鞐愲姅 頃措嫻 欤检嫕鞚� 2025雲� 8鞗� 21鞚� 氚滍枆鞚胳溂搿滊秬韯� 鞝滍暅欤茧 旆摑霅橃柎 攴鸽偁 雽�旮堨澊 歆�旮夒悩鞐堧嫟瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 靹滊電� 霕愴暅 Matthew Leonard鞚� 2025雲� 8鞗� 18鞚检棎 6,937欤茧ゼ 毵る弰頃橃棳 齑濎垬鞚� $611,644.31鞚� 鞏混棃雼る姅 氤勲弰鞚� 毵り皝霃� 瓿奠嫓頃╇媹雼�. 鞝滌稖鞛愲姅 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 鞚胳頃╇媹雼�.
ANI Pharmaceuticals (ANIP) avis Form 144 indique une proposition de vente de 2 528 actions ordinaires restreintes par ou pour une personne identifi茅e via Morgan Stanley Smith Barney sur le NASDAQ, pour une valeur de march茅 totale de 229 075,98 $ et une date approximative de vente au 25/08/2025. Le d茅p么t pr茅cise que ces actions ont 茅t茅 acquises en tant qu'actions restreintes aupr猫s de l'茅metteur le 21/08/2025 et pay茅es 脿 cette date. Le formulaire divulgue 茅galement une vente distincte par Matthew Leonard de 6 937 actions ordinaires le 18/08/2025, pour des produits bruts de 611 644,31 $. Le d茅clarant certifie qu'il n'existe aucune information d茅favorable mat茅rielle non divulgu茅e.
ANI Pharmaceuticals (ANIP) Form 144-Mitteilung weist auf einen geplanten Verkauf von 2.528 eingeschr盲nkten Stammaktien durch oder f眉r eine identifizierte Person 眉ber Morgan Stanley Smith Barney an der NASDAQ hin, mit einem Gesamtmarktwert von $229.075,98 und einem ungef盲hren Verkaufstermin am 25.08.2025. Die Einreichung gibt an, dass diese Aktien am 21.08.2025 als eingeschr盲nkte Aktien vom Emittenten erworben und an diesem Datum bezahlt wurden. Das Formular offenbart au脽erdem einen separaten Verkauf von 6.937 Stammaktien durch Matthew Leonard am 18.08.2025 mit Bruttoerl枚sen von $611.644,31. Der Einreicher best盲tigt, keine nicht offengelegten, wesentlichen nachteiligen Informationen zu haben.
FAQ
What does ANIP Form 144 disclose about proposed sales?
Who sold shares recently according to the filing for ANIP?
When were the 2,528 shares acquired and what type were they?
Which broker is handling the proposed sale in the ANIP Form 144?
Does the filing state any undisclosed material information about ANIP?
